Phase 2 and 3 trials of doublet and triplet lenalidomide-based induction treatments for transplant-eligible and transplant-ineligible patients
| Regimen . | N . | After induction . | After ASCT . | PFS . | OS . | Reference . | ||
|---|---|---|---|---|---|---|---|---|
| CR + PR (best response), % . | CR/ ≥ VGPR (best response), % . | CR + PR, % . | CR + nCR, % . | |||||
| RD vs | 223 | 81 | 5/50 | NR | NR | median, 19 mo | median, not reached | 9 |
| Rd | 222 | 70 | 4/40 | NR | NR | median, 25 mo | median, not reached | |
| (P = .02) | (P = .4) | |||||||
| RVD | 66 | 100 | 29 (39)*/67 | NR | NR | 18 mo, 75% | 18 mo, 97% | 69 |
| RVD vs | 42 | 83 | 24 (40)*/50 | NR | NR | NR | NR | 72 |
| VCD vs | 32 | 75 | 22 (31)*/41 | |||||
| RVCD | 42 | 86 | 24 (33)*/57 | NR | NR | NR | NR | 73 |
| RVDD | 57 | 4 cycles, 96 | 4 cycles, NR (30)*/58 | NR | NR | NR | NR | |
| Regimen . | N . | After induction . | After ASCT . | PFS . | OS . | Reference . | ||
|---|---|---|---|---|---|---|---|---|
| CR + PR (best response), % . | CR/ ≥ VGPR (best response), % . | CR + PR, % . | CR + nCR, % . | |||||
| RD vs | 223 | 81 | 5/50 | NR | NR | median, 19 mo | median, not reached | 9 |
| Rd | 222 | 70 | 4/40 | NR | NR | median, 25 mo | median, not reached | |
| (P = .02) | (P = .4) | |||||||
| RVD | 66 | 100 | 29 (39)*/67 | NR | NR | 18 mo, 75% | 18 mo, 97% | 69 |
| RVD vs | 42 | 83 | 24 (40)*/50 | NR | NR | NR | NR | 72 |
| VCD vs | 32 | 75 | 22 (31)*/41 | |||||
| RVCD | 42 | 86 | 24 (33)*/57 | NR | NR | NR | NR | 73 |
| RVDD | 57 | 4 cycles, 96 | 4 cycles, NR (30)*/58 | NR | NR | NR | NR | |
CRD indicates cyclophosphamide, lenalidomide, dexamethasone; NR, not reported; RD, lenalidomide, high-dose dexamethasone; Rd, lenalidomide, low-dose dexamethasone; RVD, lenalidomide, bortezomib, dexamethasone; RVCD, lenalidomide, bortezomib, cyclophosphamide, dexamethasone; RVDD, lenalidomide, bortezomib, pegylated liposomal doxorubicin, dexamethasone; and VCD, bortezomib, cyclophosphamide, dexamethasone.
At least near CR.